Audrey Sigmund

Imposter Syndrome, Burnout, and Maladaptive Perfectionism Among Oncology Professionals: A Global Cross-Sectional Study. Read the full article. bit.ly/4d5cW3G

TOMORROW we’re launching our DLBCL webinar series! Join @PallawiTorkaMD and Emily Ayers as they tackle treatment decisions in older patients — a conversation we all need in real-world practice. Register at the link below and save your spot! us06web.zoom.us/webinar/regist…

Join the #BrighamBEI for Leadership in #MedEd, a new 4 part series for medical educators looking to build leadership skills, think strategically, and advance their careers. Kicks off April 8! Register: bit.ly/BEI_Leadership @BrighamFellows @BrighamRadOnc @harvardneuromds

Zanwar et al - POD24 in WM. • 253 pts all Rx with 1L BR • 5y PFS / OS 65% / 87% • CXCR4 mutn worse prog (med PFS 3.3 v 8.8y • POD24 (11%) assoc inf OS 71 v 86% Not surprising but good to have data. #lymsm ashpublications.org/bloodadvances/…

💬 Viewpoint: Mass abstract submissions in #MedEd have led to inflated metrics, less meaningful research, and misaligned incentives for trainees and institutions. ja.ma/4qlJES1

Y Wang et al - ritux Maint after 1L BR in MCL • 703 pts with ORR to 1L BR at 3mo post • retrospect • 56% R Mx, 44% no Mx (similar features) • landmark analy: med EFS 49.9 mo with Mx, 29.7mo without, also OS benefit. Confirms role of MxR in MCL #lymsm ashpublications.org/bloodadvances/…

The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ASH_hematology

Herrera et al - 3y FU SWG 1826 - BV-AVD vs Nivo-AVD 1L III/IV Hodgkin - PFS benefit signif: 82% vs 91% - High & low PFS benefit - Particularly striking benefit older pfs (& adolescents) - No myeloid malig in either arm Fantastic data with this regimen #ASH25 #lymsm

Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it. Read the review “Strategies to Reinvigorate the Bedside Clinical Encounter,” the latest in the Medical Education series, by Brian T. Garibaldi, MD, MEHP, and Stephen W. Russell, MD, from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews): nej.md/4nUirnP

Learn more about clinical outcomes with a treatment option for 3L+ DLBCL adult patients. Click here hubs.ly/Q03S3vC30 to discover clinical trial efficacy, safety data, dosing, monitoring & management considerations for select adverse reactions, and more.

Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma aacrjournals.org/clincancerres/…

Optimising treatment strategies in older patients with mantle cell lymphoma - The Lancet thelancet.com/journals/lance…

Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy? ashpublications.org/blood/article-… Wonderful to work with Dr Laurie Sehn on this review highlighting our approach to relapsed FL #lymsm @BloodPortfolio @WilmotCancer

Population-Wide Introduction of Dose-Adjusted EPOCH-R In High-grade B-cell Lymphoma with MYC/BCL2 Rearrangements, DLBCL Morphology | Blood Advances | American Society of Hematology ashpublications.org/bloodadvances/…

#Hematology Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell #Lymphoma #DLBCL | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #lymsm ascopubs.org/doi/10.1200/JC…

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN Study ashpublications.org/bloodadvances/…

This study followed 873 patients with mantle cell lymphoma (MCL) for a median of 7 years. The 5-year incidence of MCL in CNS was only 2.8%, but 9.9% for those with blastoid/pleomorphic subtype. buff.ly/rHkpvJc

🚨 AI won’t replace doctors… but it can prevent them from learning how to think. A critical article in @NEJM shows that if introduced too early in medical training, it weakens clinical reasoning. ✅ A good doctor will always need critical thinking. N Engl J Med 2025;393:786

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. @JCO_ASCO ascopubs.org/doi/full/10.12…